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Abstract 
Background: Whilst diagnostic pathways for children with rare conditions have shown marked improvement, 
concerns remain about the care children with rare conditions receive at the level of the health care provider. There is, 
therefore, a need to improve our understanding of the health care received and explore the development of bench-
marks that can be regularly monitored.
Methods: Patients and parents with rare conditions at a tertiary children’s hospital were approached to complete 
a questionnaire-based survey that enquired on their experience of clinical care. The survey explored six key themes: 
diagnosis; provision of information; availability of support; satisfaction with healthcare team; awareness and support 
for life-limiting conditions; and participation in research.
Results: 130 questionnaires were completed on behalf of 134 patients between 2018 and 2020. Of these, 114 (85%) 
had received a formal diagnosis, 5 (4%) had a suspected diagnosis and 15 (11%) were undiagnosed. Of the 114 who 
had received a diagnosis, 24 (20%) were diagnosed within 6 months of developing symptoms, and 22 (20%) within 
1–3 years. Seventy patients (53%) reported that they were given little or no information around the time of diagnosis, 
whilst 81 (63%) felt they were currently well supported, mostly from family members, followed by friends, hospital 
services, school, other community based healthcare services and lastly, primary care. Of the 127 who were asked, 88 
(69%) reported a consistent team of healthcare professionals taking overall responsibility for their care, 86 (67%) felt 
part of the team, 74 (58%) were satisfied with the level of knowledge of the professionals, and 86 (68%) knew who to 
contact regarding their condition. Of the 91 who were asked, 23 (25%) were aware their child had a life limiting condi-
tion, but only 4 (17%) were receiving specialist support for this. Of 17 who were asked about research, 4 (24%) were 
actively participating in research, whilst the remainder were all willing to participate in future research.
Conclusions: The survey provides a unique insight into the experience of patients and parents within a specialist 
centre and the benchmarks that it has revealed can be used for future improvement in services.
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Background
Rare diseases, or conditions, are defined as those that 
affect less than 1 in 2000 of the population [1]. There 
are probably around 8000 discrete rare conditions that 
affect 3 million people in the United Kingdom (UK) [2, 
3] and around 75% of these may be children and can have 
life-limiting or disabling effects [4, 5]. Many diseases are 
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chronic, offer no effective treatment and are frequently 
incurable [5]. The rare disease plans that have been 
developed by several countries provide important guid-
ance for improving health and social care but their imple-
mentation is uneven across countries [6] and the effect of 
the implementation has rarely been measured at the level 
of a service provider.
Although scientific and medical advances have led 
to marked improvements in reaching a diagnosis and 
improving the prognosis of those with a rare condition 
[3], concerns remain about the time taken to reach a 
diagnosis [7, 8], the level of care that may be available to 
individual patients and their carers [9–11] and the par-
ticipation of patients in research [12]. These uncertain-
ties prevent an optimal understanding of the illness, and 
can impede advanced care planning including palliative 
care [13]. The quality of life of the carers as well as the 
patients with a rare condition can be markedly affected 
[3, 14–16] but it is unclear as to the level of support that 
is available for the routine family. It is possible that stud-
ies that consult expert patient or professional groups are 
prone to some selection bias and some studies in the 
past may have been based on historical experience that 
predates the recent advances in diagnostics and thera-
peutics. Many studies have also had limited value due to 
their condition-specificity and not including a broader 
variety of rare conditions [14]. To understand the cur-
rent impact of the rare condition on patients and fami-
lies with rare conditions and the care they receive locally, 
there is a need to explore new methods that can continu-
ously monitor patient/parented reported experience of 
the available support and clinical care as well as partici-
pation in research. In January 2017 the Office for Rare 
Conditions was founded in Glasgow, Scotland, following 
funding from the Glasgow Children’s Hospital Charity. 
The aim of the Office was to develop local solutions for 
raising awareness of rare conditions amongst health-
care professionals, to enhance support and clinical care 
of patients with rare conditions, and to promote partici-
pation in research. The aim of the current study was to 
measure these aspects at a specialist children’s hospital in 
the UK through a questionnaire survey. It is anticipated 
that the results would provide a current benchmark that 
can be used for improving local services for all people 
with rare conditions.
Methods
In April 2018 the Office developed a questionnaire to 
determine the quality of care patients with rare condi-
tions received at a tertiary children’s hospital in Glas-
gow. The questionnaire was developed following input 
from the Office’s Patient Advisory Group, the Steer-
ing Committee and external organisations including 
the Genetic Alliance and consisted of questions on six 
themes including: 1. diagnosis; 2. provision of infor-
mation; 3. availability of support; 4. satisfaction with 
healthcare team; 5. awareness and support for life-lim-
iting conditions; 6. participation in research (Table 1). 
The majority of questions had a binary response and 
could, therefore, be analysed quantitatively, however 
there was an option for comments following each ques-
tion to enrich qualitative data. Further questions were 
added to the original questionnaire in January 2019 
exploring theme 5; and in February 2020 questions 
were included on theme 6 (Table 1). The questionnaire 
did not collect any personally identifiable fields and had 
been locally approved as an evaluation of routine health 
care.
Between April 2018 and March 2020, the Office for 
Rare Conditions in Glasgow approached patients and 
carers who were in the outpatient waiting area, in the 
inpatient wards, who were visiting the Office’s exhibi-
tion stand in the Royal Hospital for Children, Glasgow 
or attending any education seminars organised by the 
Office and asked them to complete the above ques-
tionnaire in an electronic or a paper form. In addition, 
the electronic questionnaire was also promoted by the 
Office’s social media platforms including Facebook (@
orcglasgow) and Twitter (@orcglasgow). Any patient 
with a rare condition, or parent/carer with a child 
diagnosed or awaiting diagnosis of a rare condition 
was eligible to complete the questionnaire if they were 
attending any hospital within the NHS Great Glasgow 
& Clyde Health Board. Although there were no exclu-
sion criteria for completing the survey, the current 
report focuses on those patients who presented under 
the age of 18 years.
The quantitative aspects of the questionnaire were ana-
lysed using descriptive statistics. Qualitative responses 
were grouped and categorised.
Results
Between June 2018 and March 2020, 130 questionnaires 
had been completed and returned on behalf of 134 peo-
ple. Four parents answered the questionnaire in support 
of both of their affected children. Of the 130 question-
naires, 115 (88%) were completed by parents/carers, two 
(2%) were completed by grandparents, and the remaining 
13 (10%) were completed by the patients themselves. Of 
the 130 questionnaires, six (5%) were not fully completed 
due to time constraints. No participants reported any dif-
ficulties with answering the questionnaire. Of the 56 who 
responded to the question about the location of their 
specialist care, 48 (86%) attended the Royal Hospital for 
Children in Glasgow.
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Table 1 Questionnaire. Contents of  the  questionnaire including  the  responses available and  the  date questions were 
added
Participant information Responses available Date added
Are you a patient or parent/carer of a child with a rare condition? Patient June 2018
Parent/carer
Other—please specify
Do you or your child attend a hospital in Glasgow? (Please specify) Yes June 2019
No
Theme 1: Diagnosis
 Have you or your child been formally diagnosed or is it sus-
pected that you have a rare condition?
Formally diagnosed June 2018
Suspected to have a rare condition
Currently undiagnosed
If currently undiagnosed, how long has it been since you first 
reported your or your child’s symptoms to a healthcare profes-
sional?
 Which rare condition do you or your child have or is it suspected 
that you or your child have? Please enter N/A if undiagnosed
June 2018
 At what age did you or your child first develop symptoms? June 2018
 How long did it take to receive a diagnosis from the time you 
first approached a healthcare professional about your or your 
child’s symptoms? Please enter N/A if undiagnosed
June 2018
Theme 2: Provision of Information
 At time of diagnosis, or suspected diagnosis, how much informa-
tion were you given about the condition?
Lots of information was given June 2018
Adequate information was given
Little information was given
No information was given
N/A (currently undiagnosed)
 Where did/do you find information about this condition? Through a healthcare professional June 2018
Through the literature/website of a patient support organisation
N/A (currently undiagnosed)
Other (please specify)
 Do you feel you have enough information on this condition? Yes, I feel I know a lot about this condition June 2018
Yes, I have some information about this condition and am satisfied 
with what I know
No, I have access to some information, but would like to know 
more about this condition
No, I don’t know anything about the condition
Currently undiagnosed
Theme 3: Availability of support
 Have you had the opportunity to meet another person/family 




If you haven’t, would you like to be given such an opportunity?
 How much support do you or your child receive in every day life 












 Do you know of a support group/patient association for your 
condition or for undiagnosed conditions?
Yes June 2018
No
 Are you a member of this or any other patient support group? Yes June 2018
No
 Do you feel well supported generally? Yes June 2018
No
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Diagnosis
Of the 134 patients, 114 (85%) had been formally diag-
nosed, 15 (11%) were undiagnosed and five (4%) had a 
suspected diagnosis. Of the 114 patients with a defini-
tive diagnosis, all respondents disclosed their diagno-
sis and this included 103 different conditions, with nine 
patients who had more than one rare condition (Table 2). 
Of the 103 conditions, 27 (26%) of these were syndromal. 
Other organ systems included 16 musculoskeletal/der-
matological (15%); 10 neurodevelopmental (10%); eight 
cardiovascular (8%); seven gastrointestinal (7%); seven 
neuromuscular (7%); six endocrine (6%); six oncological 
(6%); five haematological/ immune disorder (5%); four 
renal (4%); two lysosomal (2%); two metabolic (2%); one 
ENT (1%). one ophthalmological (1%); and one respira-
tory condition (1%).
Age at first concern
Of the 114 patients with a formal diagnosis, age at first 
concern ranged from the antenatal period to age 16 years 
of life (Fig. 1a). Symptoms/signs were first recognised at 
birth in 48 (42%) and there were antenatal concerns in 15 
(13%). Of these 114, 4 (3.5%) had either no symptoms or 
did not specify the age at first concern.
Time to diagnosis
The time taken to reach a formal diagnosis from initial 
concern ranged from antenatally to 17 years. Of the 114 
patients 24 (21%) received a diagnosis within 0–6 months 
of developing symptoms, 22 (19%) obtained a diagno-
sis within 1–3  years, and 18 (16%) obtained a diagnosis 
in the neonatal period (Fig. 1b). A further three (3%) did 
not specify how long it took to obtain a diagnosis, and 
one patient (1%) was diagnosed following their death. Of 
those awaiting a formal diagnosis or who had a suspected 
diagnosis, five respondents did not specify the time they 
had been waiting for a diagnosis. In the remaining 15 
the median time awaiting a formal diagnosis was 7 years 
(range, 0.5, 30).
Age at diagnosis
Of the 114 patients with a formal diagnosis, 71 (62%) 
were diagnosed before the age of 3  years (Table  2). Of 
these 71 16 (23%) were diagnosed between the age of 
6–12 months, 14 (20%) were diagnosed between the age 
Table 1 (continued)
Participant information Responses available Date added
Theme 4: Satisfaction with Healthcare Team
 With regards to you/your child’s care, is there one specialist 
service that takes the lead?
Yes June 2018
No
If yes, which service at which hospital takes the lead
 How satisfied are you with the following?
Having a consistent team of health professionals taking overall 
responsibility for you/your child’s health
The overall support that you get from health professionals for 
you/your child
Feeling that you are part of a health care team looking after you/
your child
How much health professionals know about you/your child’s 
condition
Knowing which healthcare professional to contact for guidance/
support with your/your child’s condition
Extremely satisfied June 2018
Satisfied
Neither satisfied or dissatisfied
Dissatisfied
Extremely dissatisfied
Theme 5: Awareness and support of limiting conditions
 Do you think your child has a life limiting condition Yes January 2019
No
Don’t know
 If yes, have you received special support for that? Yes January 2019
No
Don’t know
 If yes, what service has provided the support January 2019
Theme 6: Participation in research
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Table 2 Description of the rare conditions that were encountered








Cardiovascular number of patients: 9 Aortic stenosis X
Bicuspid aortic valve X
CC1CNA1c heart defect X
Coarctation of the aorta X
Congenital heart disease XX
Hypoplastic left heart X
Unbalanced AVSD X
WPW Syndrome X






ENT number of patients: 1 Deaf in right ear X
Gastrointestinal number of patients: 9 Achalasia X
Alagilles X
Chronic pseudo obstruction of large colon X
Giant exomphalos X
Hirschprungs disease XXX
Congenital diaphragmatic hernia X
Tracheo oesophageal fistula X




Chronic mucocutaneous candidiasis X
`HSP X
Hypergammaglobulinaemia X
Lysosomal number of patients: 4 Batten disease CLN2 X X
MPS 1—Hurler syndrome XX
Metabolic number of patients: 2 Glycogen storage disease IX X
MCADD X









Malignant infantile osteoporosis X
Mandibulofacial dystosis with microcephaly X
Marfan X
Mixed connective tissue disorder X XX
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Table 2 (continued)












Cornella de lange X XX
CTNNB1 syndrome X
Joubert syndrome X
PAK1 neurodevelopmental disorder X
Periventricular leukomalacia X
Rett syndrome X X
Riboflavin transporter deficiency X
William syndrome X
Neuromuscular number of patients: 7 Adems disease X
DMD X
M.E.R.R.F X
Small fibre neuropathy X
Spinal muscle atrophy type 1 X
Sturge Weber X
Worster drought syndrome X






Ophthalmological number of patients: 1 Bilateral congenital cataracts X




Respiratory number of patients: 1 NEH1 interstitial lung disease X
Syndrome number of patients: 37 Bardet Biedi syndrome X
Beckwith-wiedemann syndrome X
Chromosome 2 deletion X
Chromosome 7 partial deletion X
Chromosome 8 disorder X
Chromosome 8 disorder—short arm dele-
tion, long arm duplication
X
CLTC chromosome abnormality X
Deletion of 10p gene 13-15p X
Di George XX
Edwards/trisomy 18 X
Inverted duplication and deletion of 8p X
Mosaic ring 14 X
Mowat Wilson syndrome X
Noonan syndrome X X
Patau/trisomy 13 XX X
Prader Willi
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of 1 and 3 years, and 12 (17%) were diagnosed both ante-
natally and neonatally (Fig.  1c). There were 37 patients 
who were diagnosed between the age of 3 and 18  years 
(Table 2). Of these 37, 18 (49%) were diagnosed between 
the age of 3 and 6 years, 7 (19%) were diagnosed between 
age of 6 and 12  years, and 12 (32%) were diagnosed 
between the age of 12–18 years. Six did not disclose their 
age at formal diagnosis.
Provision of information
At the time of diagnosis 59 (45%) of the 130 respondents 
felt they were provided little information about the con-
dition, with 11 (8%) reporting they were given no infor-
mation at all (Fig. 2). Information was received primarily 
from healthcare professionals in 45 (35%) respondents, 
this included the medical practitioners and the wider 
healthcare team, 29 (22%) received it from literature at 
patient support websites, and 15 (12%) received informa-
tion from a mixture of both healthcare professionals and 
the literature at patient support websites. The remain-
ing 29 (22%) with a formal diagnosis received the infor-
mation from a range of sources including peer support 
groups, social media and other web-based resources. Two 
respondents (1.5%) had difficulty finding information, 
and one (0.8%) respondent could not find any informa-
tion at all about their condition due to its rarity. Of the 
130 respondents, 52 (40%) reported to be content with the 
information they had received whilst only 4 (3%) reported 
that they had limited knowledge on their condition.
Availability of support
Of the 129 respondents to this section, 81 (63%) reported 
that they were well supported. This support was obtained 
from a range of sources to a variable extent. The major-
ity of support was reported to have been received from 
family members, followed by friends, hospital services, 
school staff, other community-based health care ser-
vices and lastly, primary care (Fig. 3). Of these, 43 (33%) 
reported that they did not receive any support from their 
primary health care practitioner and five (4%) did not feel 
seeking support from primary care was appropriate. Of 
the 129 respondents, 75 (58%) had met an individual or 
a family with the same condition and of the remaining 
54, 18 (33%) would have liked the opportunity to meet 
another affected person or family, four people (7%) did 
not wish to, and 32 (59%) participants did not specify 
their preference. There were 81 (63%) respondents who 
were aware of a support group and 76 (59%) were also a 
member of a support group. Thus, over 90% of respond-
ents who were aware of a support group were also a 
member of that support group.
Satisfaction with the health care team
Of the 127 respondents to this section, 78 (61%) could 
identify one specialist service that clearly took the lead 
for their or their child’s care and 86 (68%) knew of a 
named person who they could contact for their rare 
condition (Fig.  4). Of 128 respondents to the question 
on satisfaction with the health care team, 88 (69%) were 
either satisfied or extremely satisfied with the health care 
professionals taking overall responsibility for the clini-
cal care of the rare condition and 96 (75%) reported to 
be well supported; 86 (67%) felt part of the team and 74 
(58%) were satisfied with the knowledge that the health 
care team had about the rare condition.
Table 2 (continued)








Primary ciliary dyskinesia X X
Treacher Collins syndrome XX
Trichothiodystrophy X
Trisomy 14 XXX




16p11.2 micro deletion X
22q11.2 deletion syndrome X
The table below shows the 103 different rare conditions in the 114 patients with a formal diagnosis. Nine patients had more than one rare condition
ALL acute lymphoblastic leukaemia, AVM arteriovenous malformation, AVSD atrioventricular septal defect, CKD chronic kidney disease, CTLC cutaneous T-cell 
lymphoma, DI diabetes insipidus, DMD duchenne muscular dystrophy, HSP Henoch Schönlein purpura, MCADD medium chain acyl CoA dehydrogenase deficiency; 
MPS 1 mucopolysaccharidosis type 1, MRKH Mayer Rokitansky Kuster Hauser Syndrome, PMDS Persistent Mullerian Duct Syndrome, WPW Wolff–Parkinson–White
Page 8 of 13Hytiris et al. Orphanet J Rare Dis           (2021) 16:65 
Awareness and support of life‑limiting conditions
Of the 91 respondents to this section, 23 (25%) reported 
that they were aware that their child had a life-limiting 
condition and 30 (33%) did not know whether their child 
had a life-limiting condition. The remaining 38 (42%) did 
not feel their child had a life-limiting condition. Of the 23 
respondents who felt their child had a life-limiting condi-
tion, only four (17%) reported to have received specialist 
support for this. Two (9%) had received specialist pal-
liative support; one (4%) had access to clinical psychol-
ogy, and the fourth had community support. A further 
two (9%) participants did not know whether they had 
received any support and the remaining 17 (74%) did not 
receive any support.
Participation in research
Of the 17 respondents to this section, only four (24%) 
were actively participating in research whilst the remain-
ing 13 (76%) all reported that they would be interested in 
taking part in future research.
Discussion
The results of this survey provide a unique and objective 
insight into the health care experience of patients and 
their families at a regional specialist centre in the UK. It 
explores key topics including diagnostic timeframes, pro-
vision of information and support, wider healthcare team 
involvement, research participation and awareness and 
support for life-limiting conditions.
The results show that about 15% of the respondents 
were diagnosed within the neonatal period whilst a fifth 
had obtained a diagnosis within 6  months of develop-
ing symptoms and another fifth obtained a diagnosis 
within 1–3 years. With previous studies showing around 
40% of patients having difficulty obtaining a diagno-
sis [14, 17, 18], the current study shows that 85% of the 
respondents received a diagnosis in childhood, and 80% 
of these diagnoses were within a shorter period than 
the 5-year time frame that is often reported [6, 19, 20]. 
Many previous studies have focussed only on a specific 
cohort of rare conditions and have, thereby, highlighted 
specific challenges associated with individual conditions. 
A strength of the current survey was the large range of 
rare conditions that had been covered, thus the results 
can be applied more generally. It is possible that several 
disease specific factors may have influenced the care 
outcomes examined in this study but an investigation of 
these factors was not within the scope of this work. There 
was no sample bias with only a maximum of five patients 
with the same condition. However, there may have been 
a selection bias as participants were recruited through 
social media platforms and via independent representa-
tives approaching families for written responses.
Although the majority of participants did obtain a for-
mal diagnosis within childhood, 4% had a suspected diag-
nosis and 11% were currently undiagnosed within the 
study. A delay in diagnosis can lead to patient or family 
stress and frustration, unnecessary investigations and 
disease progression [7, 8]. Factors that contribute to diag-
nostic delays include limited awareness amongst health-
care professionals and the public, inadequate testing 
opportunities, long waiting times and delays in obtaining 
results [8].
Patients with a rare condition should have a high stand-
ard of medical knowledge, easily accessible care path-
ways, research and treatment opportunities [2], yet this 
survey, along with some others [8, 21, 22] has shown the 
lack of information that parents had at initial diagnosis. 
Limited knowledge about their own condition can cre-
ate major challenges for patients’ abilities to seek health 
care [23]. The current study confirmed this with over half 
of respondents who felt they were provided little or no 
information about the condition at the time of diagnosis, 
and only 40% reported to be content with the information 
they had received. Given that the majority of the affected 
children presented in early infancy, efforts for provision 
of information from the healthcare team at this critical 
period need to be intensified. This study considered the 
healthcare team as a whole, including the lead medical 
clinician and wider team, however looking at individual 
clinicians in their role in providing support and informa-
tion at the time of diagnosis requires further study.
Patient support groups perform an increasingly vital 
role in the diagnosis and management of rare condi-
tions, and are an important source of data surrounding 
these conditions [10, 24, 25]. Often they provide the sole 
source of information for patients and families [24]. It 
was interesting to note that over half of the respondents 
were a member of a support group and almost a quarter 
relied on peer support groups and social media rather 
than health care professionals as their primary source of 
information emphasising the critical role played by these 
(See figure on next page.)
Fig. 1 a Age at first concern. Participants who had a formal diagnosis were asked to report at which age they first developed concerns, n = 114. 
b Length of time taken to reach diagnosis from initial concern. Participants were asked to report the length of time taken from initial concern to 
obtaining a formal diagnosis, n = 114. c Age at formal diagnosis. The age at formal diagnosis was calculated following the responses to age of first 
concern and time taken to reach a diagnosis, n = 114
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groups, Other reports in similar settings suggest that 
membership of support groups may be less frequent [14]. 
Online patient networks can be a promising resource for 
peer support [26] and with increasing acceptability of 
technology across all ages [27] internet-based support 
groups may be of benefit for patients as well as their 
carers [28]. Given the wide range of conditions covered 
in this survey it is not surprising that a substantial pro-
portion of respondents were not members of a support 
group and whether online support groups need to be 
particularly condition specific needs further exploration 
in the future.
Presently, there are very limited studies that explore 
the impact of rare conditions in children and their 
families [14]. The current survey explored the support 
from a variety of sources including family, the health-
care team, primary health care practitioners, other 
community based healthcare, schools and friends and 
showed that almost two-thirds of people felt well sup-
ported and highlighted the important role played by 
family members. Although the primary health care 
practitioner commonly serves as the point of access to 
specialist services in the UK, becoming familiar with 
all rare conditions is generally felt to be difficult espe-
cially in the primary care setting [9] and this can be 
compounded by the fact that often patients with rare 
conditions do not feel “unwell”, but perhaps just dif-
ferent [9] and care often involves multiple disciplines 
[15]. It was reassuring to note that a large majority of 
Lots of informaon was given
Adequate informaon was given
Lile informaon was given
No informaon was given
N/A (currently undiagnosed)
Fig. 2 Provision of information at time of diagnosis. Participants 
stated how much information they were provided at the time 
of diagnosis, n = 130. The majority of patients were given no 
information (n = 59, 45%); 24 were given adequate information 
(18%); 22 were given lots of information (17%); and 11 were given no 






















Fig. 3 Availability of support. Participants were asked to rate availability of support from a wide variety of sources, n = 129
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participants felt they had a consistent team of health-
care professionals taking overall responsibility of their 
condition and were satisfied with how much health-
care professionals know about their condition. It has 
often been suggested that the care of the patient with 
a rare condition is poorly coordinated [17]. It was, 
therefore, encouraging to discover that over two thirds 
of respondents felt part of the healthcare team in this 
survey and knew who to contact for guidance and the 
majority felt one specialist service had taken the lead. 
Overall, three quarters of respondents were satis-
fied with the support they received from healthcare 
professionals.
Support is essential at the time of diagnosis, however 
it is also crucial throughout the journey of a patient 
with a rare condition, particularly as many conditions 
can be life limiting or debilitating [5]. The current sur-
vey shows that 75% of families may not have a clear 
understanding of whether their child has a life limit-
ing condition or not, perhaps reflecting on the lack of 
discussion on this topic as well as the gaps and barriers 
that may currently exist for the provision of palliative 
and end-of life care. Communication is a fundamen-
tal component of the palliative and end-of-life patient 
experience, with the term ‘palliative’ frequently misun-
derstood. It should be greater advocated that palliative 
care can also be given alongside traditional treatments 
[13], and the gap should be bridged between medical 
and palliative services, to allow for advanced care plan-
ning. Additionally, of those who felt their child did have 
a life-limiting condition, only a small percentage (17%) 
felt that they were being provided with specialist sup-
port for this.
Research is considered to be a vital aspect of improv-
ing the care of people with rare conditions [5, 14]. As 
the question enquiring whether patients/families’ 
involvement in research was added more recently in 
the survey, the response numbers were small, and only 
a quarter of respondents were actively taking part in 
research whilst the remainder were all keen on partici-
pating in research. There are many factors that could 
play a role in the limited participation, for example, 
lack of awareness of current research trials [17], selec-
tive recruitment criteria, geographical challenges, 
socioeconomic status [6, 12] or the time commitments 
when already caring for a child who may need around 
the clock care [5]. The present questionnaire could 
be adapted to explore this further and could even be 
used as a means of recruiting patients for future study. 
A recent study from 63 countries showed that just 
over one third of respondents actively participated in 
0 50 100 150
Knowing which healthcare professional to contact for
guidance/support with your/your child's condion
How much health professionals know about you/your child's
condion
Feeling that you are part of a health care team looking aer
you/your child
The overall support that you get from health professionals for
you/your child
Having a consistent team of health professionals taking overall 




Neither sasfied or dissasfied
Dissasfied
Extremely dissasfied
Fig. 4 Satisfaction with healthcare team. Participants were asked to rate satisfaction with healthcare team in relation to different aspects of care, 
n = 128
Page 12 of 13Hytiris et al. Orphanet J Rare Dis           (2021) 16:65 
research (12) demonstrating that there is a global need 
for increased research participation.
Conclusion
Although their diagnoses may differ, there are many com-
monalities experienced amongst families with rare condi-
tions. Whilst the survey has shown that although there 
are several aspects of care where the results were more 
positive than expected, there are several indicators of 
care that require improvement. The indicators that we 
describe here can be considered to be key performance 
indicators that focus on the quality of care and may be of 
interest to reference centres within regional, national or 
international clinical networks such as European Refer-
ence Networks. The unique insight provided by this sur-
vey can be used as a platform to improve service delivery 
at a local level and can also act as a benchmark against 
which the quality of care can be compared across multi-
ple centres.
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